Ask AI

A Practical Framework for Clinical Integration of ADCs Into Individualized Treatment Plans for Patients With NSCLC

Gain in-depth knowledge on current antibody–drug conjugates for non-small-cell lung cancer (NSCLC), including their targets, efficacy, and safety, to guide individualized treatment plans and manage adverse events through an on-demand webcast, expert-written ClinicalThought commentary, and accompanying downloadable slides.

Share

Program Content

No activities added yet

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

AstraZeneca

Daiichi Sankyo, Inc.